Navigation Links
Ground-breaking new insight into the development of Alzheimer's disease
Date:4/22/2008

Leuven, Belgium C According to estimates there are 85,000 Alzheimer patients in our country and approximately 20,000 new cases every year. This spectacular increase is due to the increasing ageing population. Unfortunately it is still unclear precisely which ageing process forms the basis of this spectacular rise in the occurrence of the disease. VIB scientists affiliated to K.U.Leuven have discovered an important molecular link between Alzheimer's disease and the development of the typical plaques in the brains of Alzheimer patients. This discovery is an important breakthrough in the fundamental research into the cause of Alzheimer's disease.

Alzheimer's disease: a growing problem

Alzheimer's disease, a neurodegenerative disease that slowly and gradually destroys brain cells, is the most common form of dementia in the Western world. The way in which it affects the memory and mental functioning makes it one of the most frightening disorders. Over the last 15 years the amount of research worldwide into this still incurable disease has grown considerably: faster diagnosis of the disease and better treatment are essential!

Amyloid plaques and Alzheimer's disease

Alzheimer's disease is associated with amyloid plaques C i.e. abnormal accumulations of protein fragments C that form in the brain cells. A few years ago Bart De Strooper and other researchers unravelled the process by which these plaques develop in the familial form of Alzheimer's disease (less common form). -secretase, which cuts proteins at a specific location C plays an important role here. Sometimes the secretase cuts in the wrong place, which results in a by-product and thus the formation of plaques. In the most common form of the disorder the same sort of plaques are found, but there is still little known about their development mechanism.

BACE1 or A-secretase

In patients with the most common form of Alzheimer's disease the brain cells show an increase in the protein BACE1 or A-secretase. VIB researcher Sabastien Hubert and colleagues, under the direction of Bart De Strooper and in collaboration with international experts, looked into the cause of this increase.

To this end the VIB researchers checked the expression profiles of certain microRNA's, i.e. the short pieces of RNA that regulate protein production. In patients where there was an increase in the BACE1 protein, there was a significant reduction in miR-29a and miR-29b-1. This observation suggests the possible role of certain miRNA's in the increase of BACE1 and in the formation of plaques in the brains of patients with Alzheimer's disease.

On the one hand this research raises hopes for a better diagnostic test. Timely prescription of certain medicines for Alzheimer's disease results after all in a better response, and thus a better quality of life for the patient. On the other hand there is the question of whether these microRNA's could in the future form the basis of a new drug.


'/>"/>

Contact: Evy Vierstraete
info@vib.be
329-244-6611
VIB (the Flanders Institute for Biotechnology)
Source:Eurekalert

Related medicine news :

1. CEL-SCI CORPORATION Announces Results of 2008 Annual Meeting of Shareholders and Provides Update on Ground-breaking Activities Regarding Construction of Manufacturing Facility for Pivotal Phase III Cancer Trial
2. On The Go Ships 100TB Hardware Order for Ground-Breaking Cancer Imaging and Therapy Projects
3. Design-her Gals(TM) Announces the Ground-Breaking Virtual On-Line Walk for Wishes to Grant Dreams for Stage IV Breast Cancer Patients this Holiday Season Through Gal to Gal Foundation
4. John Hancocks EZ Route Post-Enrollment Education Program Wins 2008 Insight Award for Customer Advocacy in Financial Services
5. New studies add insights to infant feeding and obesity issue
6. Forecasting MDs prescriptions choice? Ask their patients, says Management Insights study
7. Defined Health Announces Final Speaker Roster and Agenda for Therapeutic Insight 2008
8. Shannon Brownlee, Author of Overtreated, to Keynote at Defined Healths 8th Annual Therapeutic Insight Conference
9. Insights on Paying for Boomers Care Needs in 20-40 Years Helped by New Report
10. 10th Annual Human Resources Conference, June 4-6: Sharing New Insights on Workforce Planning
11. Key factor in brain development revealed, offers insight into disorder
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2017)... ... January 22, 2017 , ... "Photo Cloud allows FCPX users to ... 3D slideshow with complete ease," said Christina Austin - CEO of Pixel Film Studios. ... the FCPX timeline. Presets include scenes with one, three, four or five ...
(Date:1/21/2017)... ... January 21, 2017 , ... Caronlab Australia, an Australian ... January ECRM Trade Show in Hilton Head, SC, where it benefited from outstanding meetings ... quality of its beauty and wellness products. At this trade show, the company had ...
(Date:1/21/2017)... ... ... "ProDOF is the perfect set of tools for video editors that want to create the ... Austin - CEO of Pixel Film Studios. , Video editors using ProDOF can add ... DSLR racking focus from one area into the next. ProDOF comes with 0.5 second, ...
(Date:1/21/2017)... ... January 21, 2017 , ... Phytocéane invites you to take an ... of the world with ZANZIBAR SHOWER GEL. Inspired by the beauty of Zanzibar, a ... Oil and moisturizing vegetal coral to create this gentle, crystal-clear shower gel to cleanse ...
(Date:1/21/2017)... ... January 21, 2017 , ... Northern California Medical Associates ... joined their multi-specialty medical group. The dermatology practice provides general dermatologic treatment, outpatient ... to add this excellent dermatology practice to our group’s medical services,” explains NCMA ...
Breaking Medicine News(10 mins):
(Date:1/19/2017)... , Jan. 19, 2017 This report ... current and future scenario of the global market. Large ... opioid consumption. Severe chronic constipation is a major side ... traditional laxatives. Hence, novel targeted therapy has been prescribed ... sufferers, launch of targeted medicines, and growing awareness about ...
(Date:1/19/2017)... Accuray Incorporated (Nasdaq: ARAY ) ... to set the bar for excellence in customer satisfaction. ... satisfaction rating among radiation treatment delivery systems in the ... Intelligence Briefing™. The most recent ratings trend also shows ... peers for 11 of the past 12 quarters. ...
(Date:1/19/2017)... January 19, 2017 Shire plc ... the U.S. Food and Drug Administration (FDA) has acknowledged ... Drug Application (NDA) for SHP465, a long-acting, triple-bead, mixed ... potential once-daily treatment for Attention-Deficit/Hyperactivity Disorder (ADHD). The FDA ... June 20, 2017, the designated Prescription Drug User Fee ...
Breaking Medicine Technology: